Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Sch 1385568, a new azaphilone from Aspergillus sp.

Yang SW, Chan TM, Terracciano J, Loebenberg D, Patel M, Gullo V, Chu M.

J Antibiot (Tokyo). 2009 Jul;62(7):401-3. doi: 10.1038/ja.2009.51. Epub 2009 Jun 26. No abstract available.

PMID:
19557029
2.

Caryophyllenes from a fungal culture of Chrysosporium pilosum.

Yang SW, Chan TM, Terracciano J, Boehm E, Patel R, Chen G, Loebenberg D, Patel M, Gullo V, Pramanik B, Chu M.

J Nat Prod. 2009 Mar 27;72(3):484-7. doi: 10.1021/np8006414.

PMID:
19183048
3.

Posaconazole (Noxafil, SCH 56592), a new azole antifungal drug, was a discovery based on the isolation and mass spectral characterization of a circulating metabolite of an earlier lead (SCH 51048).

Nomeir AA, Pramanik BN, Heimark L, Bennett F, Veals J, Bartner P, Hilbert M, Saksena A, McNamara P, Girijavallabhan V, Ganguly AK, Lovey R, Pike R, Wang H, Liu YT, Kumari P, Korfmacher W, Lin CC, Cacciapuoti A, Loebenberg D, Hare R, Miller G, Pickett C.

J Mass Spectrom. 2008 Apr;43(4):509-17.

PMID:
18059003
4.

Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection.

Cacciapuoti A, Halpern J, Mendrick C, Norris C, Patel R, Loebenberg D.

Antimicrob Agents Chemother. 2006 Jul;50(7):2587-90.

5.

A new 5-alkenylresorcinol sch 725681 from Aspergillus sp.

Yang SW, Chan TM, Terracciano J, Loebenberg D, Patel M, Gullo V, Chu M.

J Antibiot (Tokyo). 2006 Mar;59(3):190-2.

PMID:
16724460
6.

In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.

Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, Loebenberg D, Black TA, McNicholas PM.

Antimicrob Agents Chemother. 2006 Jun;50(6):2009-15.

7.

Structure elucidation of Sch 725674 from Aspergillus sp.

Yang SW, Chan TM, Terracciano J, Loebenberg D, Patel M, Chu M.

J Antibiot (Tokyo). 2005 Aug;58(8):535-8.

PMID:
16266128
8.

Posaconazole therapy for systemic coccidioidomycosis in a chimpanzee (Pan troglodytes): a case report.

Herrin KV, Miranda A, Loebenberg D.

Mycoses. 2005 Nov;48(6):447-52.

PMID:
16262885
9.

Hydroxylated analogues of the orally active broad spectrum antifungal, Sch 51048 (1), and the discovery of posaconazole [Sch 56592; 2 or (S,S)-5].

Bennett F, Saksena AK, Lovey RG, Liu YT, Patel NM, Pinto P, Pike R, Jao E, Girijavallabhan VM, Ganguly AK, Loebenberg D, Wang H, Cacciapuoti A, Moss E, Menzel F, Hare RS, Nomeir A.

Bioorg Med Chem Lett. 2006 Jan 1;16(1):186-90. Epub 2005 Nov 2.

PMID:
16260134
10.

In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi.

González GM, Fothergill AW, Sutton DA, Rinaldi MG, Loebenberg D.

Med Mycol. 2005 May;43(3):281-4.

PMID:
16010855
11.

New antibiotic Sch 725424 and its dehydration product Sch 725428 from Kitasatospora sp.

Yang SW, Chan TM, Terracciano J, Patel R, Loebenberg D, Chen G, Patel M, Gullo V, Pramanik B, Chu M.

J Antibiot (Tokyo). 2005 Mar;58(3):192-5.

PMID:
15895527
12.

Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections.

Carrillo-Muñoz AJ, Quindós G, Ruesga M, Alonso R, del Valle O, Hernández-Molina JM, McNicholas P, Loebenberg D, Santos P.

J Antimicrob Chemother. 2005 Mar;55(3):317-9. Epub 2005 Feb 10.

PMID:
15705637
13.

Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo.

Cacciapuoti A, Gurnani M, Halpern J, Norris C, Patel R, Loebenberg D.

Antimicrob Agents Chemother. 2005 Feb;49(2):638-42.

14.

A new anthracycline antibiotic micromonomycin from Micromonospora sp.

Yang SW, Chan TM, Terracciano J, Patel R, Loebenberg D, Chen G, Patel M, Gullo V, Pramanik B, Chu M.

J Antibiot (Tokyo). 2004 Sep;57(9):601-4. No abstract available.

15.

Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans.

Simitsopoulou M, Gil-Lamaignere C, Avramidis N, Maloukou A, Lekkas S, Havlova E, Kourounaki L, Loebenberg D, Roilides E.

Antimicrob Agents Chemother. 2004 Oct;48(10):3801-5.

16.

Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds.

Munayyer HK, Mann PA, Chau AS, Yarosh-Tomaine T, Greene JR, Hare RS, Heimark L, Palermo RE, Loebenberg D, McNicholas PM.

Antimicrob Agents Chemother. 2004 Oct;48(10):3690-6.

17.

A new antimicrobial dibenzofuran Sch 725421 from an unidentified fungus.

Yang SW, Chan TM, Patel R, Terracciano J, Loebenberg D, Patel M, Chu M.

J Antibiot (Tokyo). 2004 Jul;57(7):465-7. No abstract available.

18.

Structure elucidation of a new diketopiperazine Sch 725418 from Micromonospora sp.

Yang SW, Chian TM, Terracciano J, Loebenberg D, Chen G, Patel M, Gullo V, Pramanik B, Chu M.

J Antibiot (Tokyo). 2004 May;57(5):345-7. No abstract available.

19.

Effect of granulocyte colony-stimulating factor combination therapy on efficacy of posaconazole (SCH56592) in an inhalation model of murine pulmonary aspergillosis.

Patera AC, Menzel F, Jackson C, Brieland JK, Halpern J, Hare R, Cacciapuoti A, Loebenberg D.

Antimicrob Agents Chemother. 2004 Aug;48(8):3154-8.

20.

Posaconazole therapy of disseminated phaeohyphomycosis in a murine model.

Graybill JR, Najvar LK, Johnson E, Bocanegra R, Loebenberg D.

Antimicrob Agents Chemother. 2004 Jun;48(6):2288-91.

21.

Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles.

Chau AS, Mendrick CA, Sabatelli FJ, Loebenberg D, McNicholas PM.

Antimicrob Agents Chemother. 2004 Jun;48(6):2124-31.

22.

Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories.

Najvar LK, Cacciapuoti A, Hernandez S, Halpern J, Bocanegra R, Gurnani M, Menzel F, Loebenberg D, Graybill JR.

Antimicrob Agents Chemother. 2004 Mar;48(3):758-64.

23.
24.

Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis.

Andes D, Marchillo K, Conklin R, Krishna G, Ezzet F, Cacciapuoti A, Loebenberg D.

Antimicrob Agents Chemother. 2004 Jan;48(1):137-42.

25.

Changes in susceptibility to posaconazole in clinical isolates of Candida albicans.

Li X, Brown N, Chau AS, López-Ribot JL, Ruesga MT, Quindos G, Mendrick CA, Hare RS, Loebenberg D, DiDomenico B, McNicholas PM.

J Antimicrob Chemother. 2004 Jan;53(1):74-80. Epub 2003 Dec 4.

PMID:
14657086
26.

Activity of posaconazole in treatment of experimental disseminated zygomycosis.

Dannaoui E, Meis JF, Loebenberg D, Verweij PE.

Antimicrob Agents Chemother. 2003 Nov;47(11):3647-50.

27.

Novel fungal metabolites as cell wall active antifungals: fermentation, isolation, physico-chemical properties, structure and biological activity.

Hegde VR, Silver J, Patel M, Gullo VP, Puar MS, Das PR, Loebenberg D.

J Antibiot (Tokyo). 2003 May;56(5):437-47.

28.

A new antifungal sterol sulfate, Sch 601324, from Chrysosporium sp.

Yang SW, Buevich A, Chan TM, Terracciano J, Chen G, Loebenberg D, Patel M, Boehm E, Gullo V, Pramanik B, Chu M.

J Antibiot (Tokyo). 2003 Apr;56(4):419-22. No abstract available.

29.

Structure elucidation of a new antifungal sterol sulfate, Sch 575867, from a deep-water marine sponge (Family: Astroscleridae).

Yang SW, Chan TM, Pomponi SA, Chen G, Loebenberg D, Wright A, Patel M, Gullo V, Pramanik B, Chu M.

J Antibiot (Tokyo). 2003 Feb;56(2):186-9. No abstract available.

30.

Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays.

González GM, Tijerina R, Najvar LK, Bocanegra R, Rinaldi MG, Loebenberg D, Graybill JR.

Antimicrob Agents Chemother. 2003 Apr;47(4):1436-8.

31.

Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase.

Mann PA, Parmegiani RM, Wei SQ, Mendrick CA, Li X, Loebenberg D, DiDomenico B, Hare RS, Walker SS, McNicholas PM.

Antimicrob Agents Chemother. 2003 Feb;47(2):577-81.

32.

In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model.

Sun QN, Najvar LK, Bocanegra R, Loebenberg D, Graybill JR.

Antimicrob Agents Chemother. 2002 Jul;46(7):2310-2.

33.

Synthesis and antifungal activity of the 2,2,5-tetrahydrofuran regioisomers of SCH 51048.

Lovey RG, Saksena AK, Girijavallabhan VM, Blundell P, Guzik H, Loebenberg D, Parmegiani RM, Cacciapuoti A.

Bioorg Med Chem Lett. 2002 Jul 8;12(13):1739-42.

PMID:
12067550
34.

In vitro and in vivo activities of posaconazole against Coccidioides immitis.

González GM, Tijerina R, Najvar LK, Bocanegra R, Rinaldi M, Loebenberg D, Graybill JR.

Antimicrob Agents Chemother. 2002 May;46(5):1352-6.

35.

EmtA, a rRNA methyltransferase conferring high-level evernimicin resistance.

Mann PA, Xiong L, Mankin AS, Chau AS, Mendrick CA, Najarian DJ, Cramer CA, Loebenberg D, Coates E, Murgolo NJ, Aarestrup FM, Goering RV, Black TA, Hare RS, McNicholas PM.

Mol Microbiol. 2001 Sep;41(6):1349-56.

36.

Comparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompetent mice.

Brieland J, Essig D, Jackson C, Frank D, Loebenberg D, Menzel F, Arnold B, DiDomenico B, Hare R.

Infect Immun. 2001 Aug;69(8):5046-55.

37.

Susceptibility of pneumococci to evernimicin: effect of CO2 and different methodologies.

Hamilton-Miller JM, Shah S, Loebenberg D.

Clin Microbiol Infect. 2001 Jun;7(6):339-40. No abstract available.

38.

Novel fungal metabolites as cell wall active antifungals: fermentation, isolation, physico-chemical properties, structure and biological activity.

Hegde VR, Silver J, Patel M, Gullo VP, Yarborough R, Huang E, Das PR, Puar MS, DiDomenico BJ, Loebenberg D.

J Antibiot (Tokyo). 2001 Jan;54(1):74-83.

39.

In vitro uptake of SCH 27899 (evernimicin) by rat alveolar macrophages.

Zbaida S, Brieland J, Krieter P, Loebenberg D, Krishna G, Horne D, Lu X, Yuan Y, Hare R, Cayen MN, Patrick JE.

Antimicrob Agents Chemother. 2001 Mar;45(3):959-61.

40.

Cytokine networking in lungs of immunocompetent mice in response to inhaled Aspergillus fumigatus.

Brieland JK, Jackson C, Menzel F, Loebenberg D, Cacciapuoti A, Halpern J, Hurst S, Muchamuel T, Debets R, Kastelein R, Churakova T, Abrams J, Hare R, O'Garra A.

Infect Immun. 2001 Mar;69(3):1554-60.

41.

In vivo activity of evernimicin (SCH 27899) against methicillin-resistant Staphylococcus aureus in experimental infective endocarditis.

Boucher HW, Thauvin-Eliopoulos C, Loebenberg D, Eliopoulos GM.

Antimicrob Agents Chemother. 2001 Jan;45(1):208-11.

42.

Immunomodulatory role of endogenous interleukin-18 in gamma interferon-mediated resolution of replicative Legionella pneumophila lung infection.

Brieland JK, Jackson C, Hurst S, Loebenberg D, Muchamuel T, Debets R, Kastelein R, Churakova T, Abrams J, Hare R, O'Garra A.

Infect Immun. 2000 Dec;68(12):6567-73.

43.

Evernimicin (SCH27899) inhibits a novel ribosome target site: analysis of 23S ribosomal DNA mutants.

Adrian PV, Mendrick C, Loebenberg D, McNicholas P, Shaw KJ, Klugman KP, Hare RS, Black TA.

Antimicrob Agents Chemother. 2000 Nov;44(11):3101-6.

44.

Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice.

Connolly P, Wheat LJ, Schnizlein-Bick C, Durkin M, Kohler S, Smedema M, Goldberg J, Brizendine E, Loebenberg D.

Antimicrob Agents Chemother. 2000 Oct;44(10):2604-8.

46.

In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida.

Cacciapuoti A, Loebenberg D, Corcoran E, Menzel F Jr, Moss EL Jr, Norris C, Michalski M, Raynor K, Halpern J, Mendrick C, Arnold B, Antonacci B, Parmegiani R, Yarosh-Tomaine T, Miller GH, Hare RS.

Antimicrob Agents Chemother. 2000 Aug;44(8):2017-22.

47.

Efficacy of SCH27899 in an animal model of Legionnaires' disease using immunocompromised A/J mice.

Brieland JK, Loebenberg D, Menzel F, Hare RS.

Antimicrob Agents Chemother. 2000 May;44(5):1333-6.

48.

SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ("Ramichloridium mackenziei").

Al-Abdely HM, Najvar L, Bocanegra R, Fothergill A, Loebenberg D, Rinaldi MG, Graybill JR.

Antimicrob Agents Chemother. 2000 May;44(5):1159-62.

49.
50.

Efficacy of SCH56592 in a rabbit model of invasive aspergillosis.

Kirkpatrick WR, McAtee RK, Fothergill AW, Loebenberg D, Rinaldi MG, Patterson TF.

Antimicrob Agents Chemother. 2000 Mar;44(3):780-2.

Supplemental Content

Loading ...
Support Center